Life Sciences & Pharma
We work with leading pharmaceutical, biotechnology and medical device companies to protect and enhance their most important assets — their ideas, their people, and their future. We call it: Ideas. People. Possibilities.
Our full service offering means that we can provide a full range of legal advice to innovative life sciences and pharma companies and industry investors at every stage of the product life cycle, providing a seamless service. You will benefit from our experience of dealing with many global key players and our understanding of the key issues affecting the sector.
Creativity, technology and innovation are at the heart of everything we do. It is reflected in the way we work, as well as in the types of businesses we work with. We help bring your ideas to life by working alongside you as a trusted partner and bringing together leading commercial, corporate, data and privacy, dispute resolution, employment, immigration, intellectual property and real estate lawyers to help create, optimise, manage and protect your ideas and your business.
The global life sciences industry is always on the rise, growing more rapidly than ever over the past decade, only to accelerate further as the pandemic struck with investments pouring in.
Covid-19 has accelerated new ways of working within the pharma and biotech sectors, reprioritising R&D resources, meeting challenges and ensuring supply chain continuity, and adapting to new approaches for intellectual property protection. Whilst the future remains uncertain, in light of the response to Covid-19 life science companies are having to consider how they might operate post-pandemic, and we believe we are perfectly positioned to meet these new industry challenges and demands.
We have experience in:
- Advanced Materials, Biomaterials
- Advanced medicinal pharmaceutical products, Tissue Engineering
- Automotive and Transport
- Biotechnology (Industrial)
- Biotechnology, Drug Discovery and Drug Delivery
- Chemicals, Chemical and Process Engineering
- Clinical trials
- Commercial agreements including supply and distribution agreements
- Corporate transactions (including fundraising, IPOs and M&A)
- Diagnostics and Biomarkers
- Digitalisation, databases, patient interaction
- Dispute resolution and litigation
- Energy and Power
- Food and Agriculture
- Hardware – Advanced Processor Technologies
- Intellectual property, including IP strategies and the full spectrum of patent law
- Internet of Things, Fintech, and Open source
- Marketing and advertising
- Medical Devices and Implants
- Methods, Research and Training Tools
- Pharmaceuticals and Biologicals
- Privacy and data protection
- Product liability
- Software – Autonomy and Verification, Formal Methods, Imaging science, Machine Learning and Robotics, NLP and Text Mining
“Eight drivers of change – 2022 and beyond” (By James Davies, Lewis Silkin LLP)22 November 2022
Last year James Davies published a report the Eight Drivers of Change – the future of work for the Future of Work Hub. It identified eight key drivers of change in society as a whole, and in the workplace in particular. It considered how these interconnected drivers were accelerating change at an unprecedented scale and speed and how these changes were influencing the what, where, from where, when, how, how much/many, who and why of work.
COVID-19 vaccine counterfeits set off alarms across the globe: David Swain comments for BioWorld23 February 2021
A cooler box with 70 vials allegedly filled with counterfeit COVID-19 vaccines seized from a Chinese couple in Colombia’s El Dorado International Airport on Feb. 17 underscored the growing challenges facing pharmaceutical companies, law enforcement authorities and health care regulators around the world. David Swain comments on patient safety, company liability and the security of distribution channels in this article for BioWorld.
Government’s immigration stance on frontline workers proves controversial01 June 2020
On 1 May the Home Office published an expanded list of COVID-19 frontline workers’ occupations entitling them and their family members to a free and automatic one-year extension of leave. However, the measures announced to-date just serve to highlight that considerably more needs to be done
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP? Paul Williams writes for Life Sciences Intellectual Property Review29 May 2020
Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, writes Paul Williams.
Lewis Silkin has advised SPL Enterprises Inc. on its acquisition in Irta Dosificacio I Tecnologia S.L.21 January 2020
Lewis Silkin has advised SPL Enterprises, Inc., a Harbour Group company, on its acquisition of the majority equity interest in Irta Dosificacio I Tecnologia S.L. (trading as i-Dositecno), a producer of filling equipment for the drug and cosmetic industries. Terms of the transaction were not disclosed.